Verona Pharma (VRNA) Short Interest Ratio & Short Volume → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free VRNA Stock Alerts $15.24 -0.35 (-2.25%) (As of 04/24/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Verona Pharma Short Interest DataCurrent Short Volume6,560,000 sharesPrevious Short Volume6,400,000 sharesChange Vs. Previous Month+2.50%Dollar Volume Sold Short$105.55 millionShort Interest Ratio / Days to Cover13.3Last Record DateMarch 31, 2024Outstanding Shares80,820,000 sharesPercentage of Shares Shorted8.12%Today's Trading Volume244,005 sharesAverage Trading Volume496,440 sharesToday's Volume Vs. Average49% Short Selling Verona Pharma ? Sign up to receive the latest short interest report for Verona Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVRNA Short Interest Over TimeVRNA Days to Cover Over TimeVRNA Percentage of Float Shorted Over Time Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Verona Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20246,560,000 shares $105.55 million +2.5%N/A13.3 $16.09 3/15/20246,400,000 shares $100.16 million +1.0%N/A11.7 $15.65 2/29/20246,340,000 shares $109.17 million -5.2%11.5%10.8 $17.22 2/15/20246,690,000 shares $112.06 million -2.2%12.2%11.6 $16.75 1/31/20246,840,000 shares $125.51 million +0.7%N/A12.5 $18.35 1/15/20246,790,000 shares $121.81 million +4.0%N/A11.9 $17.94 Get the Latest News and Ratings for VRNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. 12/31/20236,530,000 shares $129.82 million +4.7%N/A11.9 $19.88 12/15/20236,240,000 shares $107.76 million -4.2%N/A13.3 $17.27 11/30/20236,510,000 shares $88.02 million +3.7%N/A16.7 $13.52 11/15/20236,280,000 shares $90.12 million +4.2%N/A17.8 $14.35 10/31/20236,030,000 shares $84.12 million +53.1%N/A17.3 $13.95 10/15/20233,940,000 shares $52.84 million -14.2%N/A12.7 $13.41 9/30/20234,590,000 shares $74.82 million +4.1%N/A15.1 $16.30 9/15/20234,410,000 shares $77.66 million +14.3%N/A13.9 $17.61 8/31/20233,860,000 shares $75.00 million +1.6%N/A11.2 $19.43 8/15/20233,800,000 shares $69.05 million +8.9%N/A10.5 $18.17 7/31/20233,490,000 shares $77.09 million +3.9%N/A8.7 $22.09 7/15/20233,360,000 shares $74.22 million +0.3%N/A8.1 $22.09 6/30/20233,350,000 shares $70.82 million +24.1%5.8%7 $21.14 6/15/20232,700,000 shares $57.02 million +1.9%4.7%5.3 $21.12 5/31/20232,650,000 shares $57.03 million +13.3%4.6%5.2 $21.52 5/15/20232,340,000 shares $48.95 million +2.2%4.1%4.3 $20.92 4/30/20232,290,000 shares $47.98 million +21.8%N/A4.1 $20.95 4/15/20231,880,000 shares $40.36 million +3.9%N/A3.1 $21.47 3/31/20231,810,000 shares $36.34 million +15.3%N/A3.1 $20.08 3/15/20231,570,000 shares $28.54 million +4.0%2.9%1.5 $18.18 2/28/20231,510,000 shares $32.37 million -7.4%2.8%1.4 $21.44 2/15/20231,630,000 shares $35.52 million +1.2%3.0%1.6 $21.79 1/31/20231,610,000 shares $35.48 million +7.3%3.1%1.7 $22.04 1/15/20231,500,000 shares $35.88 million +20.0%2.9%1.7 $23.92 12/30/20221,250,000 shares $32.66 million +95.0%2.4%1.5 $26.13 12/15/2022640,900 shares $8.21 million -4.7%1.2%0.9 $12.81 11/30/2022672,800 shares $8.68 million -14.5%1.3%2.8 $12.90 11/15/2022786,700 shares $9.73 million -8.0%1.5%3.3 $12.37 10/31/2022855,200 shares $10.95 million +12.3%N/A1.9 $12.80 10/15/2022761,500 shares $7.62 million +25.7%1.6%0.8 $10.01 9/30/2022605,900 shares $6.19 million -3.3%1.2%0.6 $10.22 9/15/2022626,500 shares $6.77 million +19.0%1.3%0.7 $10.80 8/31/2022526,300 shares $5.48 million -30.8%1.1%0.6 $10.42 8/15/2022760,100 shares $9.49 million +1,753.9%1.8%0.9 $12.48top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… VRNA Short Interest - Frequently Asked Questions What is Verona Pharma's current short interest? Short interest is the volume of Verona Pharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 6,560,000 shares of VRNA short. Learn More on Verona Pharma's current short interest. What is a good short interest ratio for Verona Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRNA shares currently have a short interest ratio of 13.0. Learn More on Verona Pharma's short interest ratio. Which institutional investors are shorting Verona Pharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Verona Pharma: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Verona Pharma's short interest increasing or decreasing? Verona Pharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,560,000 shares, an increase of 2.5% from the previous total of 6,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Verona Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Verona Pharma: Day One Biopharmaceuticals, Inc. (15.24%), Gyre Therapeutics, Inc. (0.87%), Pacira BioSciences, Inc. (8.04%), ANI Pharmaceuticals, Inc. (0.93%), Ironwood Pharmaceuticals, Inc. (14.48%), Kiniksa Pharmaceuticals, Ltd. (4.55%), Morphic Holding, Inc. (11.79%), Ligand Pharmaceuticals Incorporated (4.05%), Kura Oncology, Inc. (16.38%), Deciphera Pharmaceuticals, Inc. (12.26%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Verona Pharma stock? Short selling VRNA is an investing strategy that aims to generate trading profit from Verona Pharma as its price is falling. VRNA shares are trading down $0.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Verona Pharma? A short squeeze for Verona Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRNA, which in turn drives the price of the stock up even further. How often is Verona Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRNA, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: KNSA Short Squeeze PCRX Short Squeeze SYRE Short Squeeze LGND Short Squeeze IRWD Short Squeeze PIRS Short Squeeze DCPH Short Squeeze COLL Short Squeeze ABCL Short Squeeze GYRE Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VRNA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry